MedRx Co., Ltd Announces Consolidated Financial Results for the Fiscal Year Ended December 31, 2019; Provides Consolidated Financial Results Forecast for the Six Months Ending June 2020 and Fiscal Year Ending December, 2020
February 07, 2020
Share
MedRx Co. Ltd. announced consolidated financial results for the fiscal year ended December 31, 2019. For the period, the company's reported Net Sales were JPY 169 million compared to JPY 8 million for the same period a year ago. Operating loss was JPY 1,627 million compared to JPY 1,273 million for the same period a year ago. Loss attributable to owners of parent was JPY 1,616 million compared to JPY 1,267 million for the same period a year ago. Net loss per share was JPY 134.32 compared to JPY 126.77 for the same period a year ago.
For the year Ending June, 2020, the company expects net sales to be JPY 234 million, Operating loss to be JPY 590 million, Net loss to be JPY 593 million, and net loss per share to be JPY 43.29.
For the year Ending December, 2020, the company expects net sales to be JPY 234 million, Operating loss to be JPY 1,189 million, Net loss to be JPY 1,191 million, and net loss per share to be JPY 86.88.
Medrx Co., Ltd. is a Japan-based Company principally engaged in the research and development of pharmaceutical products. The Company produces new medicines based on percutaneous absorption formulation technology. The Company has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.
MedRx Co., Ltd Announces Consolidated Financial Results for the Fiscal Year Ended December 31, 2019; Provides Consolidated Financial Results Forecast for the Six Months Ending June 2020 and Fiscal Year Ending December, 2020